Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397943 | 0.92 | CHRNA7 (0.52) | CHRNA7EPHX2TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL6480751 | 0.83 | CHRNA7 (0.51) | CHRNA7EPHX2TAS1R3TAS1R1HDAC6 | |
| SCHEMBL6489348 | 0.81 | CHRNA7 (0.41) | CHRNA7RAB9ANPC1HDAC6 | |
| SCHEMBL6388869 | 0.81 | NAMPT (0.47) | CHRNA7EPHX2TAS1R3TAS1R1RAB9A | |
| SCHEMBL6480360 | 0.79 | KDM4E (0.42) | CHRNA7TAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL6481508 | 0.78 | CHRNA7 (0.57) | CHRNA7TAS1R3TAS1R1 | |
| SCHEMBL6489484 | 0.77 | CHRNA7 (0.52) | CHRNA7EPHX2RAB9A | |
| SCHEMBL6480686 | 0.77 | POLB (0.39) | CHRNA7RAB9ANPC1SMN1; SMN2HDAC6 | |
| SCHEMBL6479418 | 0.77 | CYP2A6 (0.38) | CHRNA7EPHX2HDAC6 | |
| SCHEMBL6395223 | 0.76 | TAS1R3 (0.47) | CHRNA7EPHX2TAS1R3TAS1R1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | claimed |
| US-6849620-B2 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PFIZER INC (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1438308-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003037896-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | CHRNA7 1187/4885EPHX2 201/4885TAS1R3 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.